Cyteir Therapeutics Inc. (CYT)
NASDAQ: CYT
· Real-Time Price · USD
3.02
-0.07 (-2.27%)
At close: Mar 15, 2024, 9:00 PM
Cyteir Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -33.22M | -40.73M | -44.45M | -46.06M | -49.08M | -49.74M | -48.92M | -42.13M | -35.67M | -29M | -22.21M |
Depreciation & Amortization | 538K | 598K | 659K | 668K | 638K | 593K | 535K | 479K | 434K | 416K | 387K |
Stock-Based Compensation | 3.29M | 3.88M | 4.47M | 4.68M | 4.95M | 4.83M | 4.23M | 3.46M | 2.47M | 1.53M | 866K |
Other Working Capital | 3.48M | 3.29M | -70K | -1.87M | -616K | -1.84M | 749K | 2.11M | -1.1M | 1.47M | -141K |
Other Non-Cash Items | 2.88M | 1.39M | 1.32M | 707K | 2.7M | 2.55M | 2.3M | 2.15M | n/a | n/a | n/a |
Deferred Income Tax | -1.96M | -319K | n/a | n/a | -2.15M | -2.15M | -2.15M | -2.15M | n/a | n/a | n/a |
Change in Working Capital | 2.68M | 1.38M | -2.53M | -2.53M | -2.28M | -1.67M | 2.17M | 2.15M | 1.2M | 3.83M | 695K |
Operating Cash Flow | -25.79M | -33.8M | -40.53M | -42.53M | -45.23M | -45.59M | -41.83M | -36.03M | -31.57M | -23.23M | -20.26M |
Capital Expenditures | -302K | -312K | -423K | -614K | -815K | -1.2M | -1.2M | -1.19M | -738K | -588K | -487K |
Cash Acquisitions | 303K | 303K | 150K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 303.00 | 303.00 | 150.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 1K | -9K | -273K | -614K | -815K | -1.2M | -1.2M | -1.19M | -738K | -588K | -487K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 842K | 749K | 326K | 242K | 116K | 14.55M | 136.22M | 216.01M | 217.12M | 202.9M | 81.24M |
Financial Cash Flow | 842K | 749K | 326K | 242K | 95.02K | 38.53K | 155.2K | 216.01K | 1.35M | 1.63M | 1.51M |
Net Cash Flow | -24.64M | -32.76M | -40.18M | -42.6M | -45.93M | -32.24M | 93.19M | 178.78M | 184.82M | 179.08M | 60.49M |
Free Cash Flow | -26.09M | -34.11M | -40.95M | -43.15M | -46.05M | -46.79M | -43.03M | -37.22M | -32.3M | -23.82M | -20.75M |